528 related articles for article (PubMed ID: 30309978)
1. Matching-adjusted indirect comparison of benralizumab
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
7. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
15. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
16. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P; Wenzel S; Rabe KF; Bourdin A; Lugogo NL; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M;
N Engl J Med; 2017 Jun; 376(25):2448-2458. PubMed ID: 28530840
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ; Celli BR; Brightling CE; Agusti A; Papi A; Singh D; Sin DD; Vogelmeier CF; Sciurba FC; Bafadhel M; Backer V; Kato M; Ramírez-Venegas A; Wei YF; Bjermer L; Shih VH; Jison M; O'Quinn S; Makulova N; Newbold P; Goldman M; Martin UJ; ;
N Engl J Med; 2019 Sep; 381(11):1023-1034. PubMed ID: 31112385
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]